The key to living longer could be tied to a surprising substance, study suggests
Researchers at the Emory University Department of Medicine in Atlanta, Georgia, discovered that psilocybin extended cellular lifespan and improved survival in aged mice.
Psilocybin is the "naturally occurring psychedelic compound produced by hallucinogenic mushrooms," as defined in the study.
Single Dose Of 'Magic Mushrooms' Provides 5 Years Of Depression Relief, Researchers Find
Psilocybin has recently received attention due to "considerable clinical evidence" for its potential in treating various psychiatric and neurodegenerative conditions, the researchers noted.
The study, published in the journal Nature, uncovered the first experimental evidence that treatment with psilocin – the "active metabolite" in psilocybin – increases longevity in aged mice.
Read On The Fox News App
This suggests that psilocybin may be a "potent geroprotective agent," the researchers wrote.
Co-author Louise Hecker of Emory University said the data suggests psilocybin impacts "multiple hallmarks of aging."
This includes reducing oxidative stress levels and preventing DNA damage, also known as preserving "telomere length." (Telomere are DNA-protein structures on the ends of chromosomes, which help to prevent cellular damage.)
Parkinson's Patients Who Take 'Magic Mushrooms' See Key Benefits, Study Finds
"Psilocybin appears to slow the 'wear and tear' that accompanies aging," Hecker said in an interview with Fox News Digital. "Mice and cells are healthier and live significantly longer."
The treatment led to "a dramatic impact on cellular life extensions" and increased the survival of mice, even when administered later in life, the researcher noted.
The mice also appeared healthier, growing back black hair that was once white.
"Most of what we know about psilocybin is clinical outcomes and what it does in the brain," Hecker commented. "These studies shed light on the fact that psilocybin has potent impacts on the entire body."
As these are the first studies showing the impact of psilocybin on aging, Hecker noted that there is still "much more to learn" about the drug's potential.
"What are the optimal dosing protocols for humans? What is the optimal age for treatment initiation for optimal benefits?" Hecker questioned.
"Is there an age, beyond which point, when treatment does not provide efficacy? Are there potential harms or adverse effects associated with long-term treatment? What are the mechanisms of its action? All these questions need to be rigorously tested."
Additional studies are needed to answer these questions and confirm whether treatment impacts lifespan, Hecker noted.
Gabe Charambides, founder of Odyssey – America's first legal psilocybin retreat, located in Oregon – said he considers these findings "compelling."
"While most human psilocybin trials have focused on mental health outcomes — depression, anxiety, PTSD — this work highlights physiological shifts, including markers of cellular aging," he said in an interview with Fox News Digital.
While Charambides' retreat doesn't test for any biological changes, he said that many guests report relief from physical ailments like chronic pain and migraines.
"Those self-reports suggest the mind–body effects the study hints at may translate to humans as well," he told Fox News Digital.
Click Here To Sign Up For Our Health Newsletter
Administration of psilocybin should differ "sharply" from mice to humans in terms of screening, preparation and safeguards, Charambides noted.
Individuals who benefit the most from psilocybin therapy include those who "feel stuck" after significant life events – like childhood trauma, divorce, career upheaval or bereavement – or people who aim to improve their mental health, he added.
Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, has emphasized the importance of administering psychedelics in a safe setting.
For more Health articles, visit www.foxnews.com/health
"Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials."
To mitigate these risks, Moss recommended that clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions.Original article source: The key to living longer could be tied to a surprising substance, study suggests
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
4 hours ago
- The Hill
Flu, COVID can reawaken dormant breast cancer cells: Study
Respiratory infections like COVID-19 and the flu can activate dormant cancer cells in breast cancer patients who are in remission, new research finds. The study, published in Nature, found that common viruses can reawaken small numbers of dormant breast cancer cells in the lungs. Researchers began investigating the link after the team noticed that U.K. patients who were in remission from breast cancer and tested positive for COVID later showed a two-fold increase in cancer-related deaths. They also analyzed a U.S. database that included nearly 37,000 patients and found that COVID infection was associated with a more than 40 percent increased risk of metastatic breast cancer in the lungs. Studies on mice found that influenza and COVID infections triggered dormant breast cancer cells after just days of infection. Within two weeks, researchers observed 'massive expansion' of the cancer cells into metastatic lesions by more than 100 times. Scientists have suspected that common viruses like Epstein-Barr can trigger some cancers. Human papillomavirus (HPV) is already documented to trigger cervical cancer. When it comes to breast cancer, however, research on human cells was limited, and it's not entirely known how the virus triggers the disease to spread. The findings suggest the body's immune response plays a role. After breast cancer goes into remission, a tiny number of cells remain dormant in lung, bone and liver tissue. Sometimes, inflammation can wake up the cells. In the mouse experiments, both influenza A and coronavirus only reawakened dormant cells if they triggered an inflammatory cytokine response. More research is needed to see if vaccination makes a difference when it comes to the possibility of reawakening dormant cells.
Yahoo
a day ago
- Yahoo
Miniature Neutrino Detector Catches Elusive Particles at Nuclear Reactor
A relatively small detector caught neutrinos from a nuclear reactor using a technique known as coherent scattering Physicists have caught neutrinos from a nuclear reactor using a device weighing just a few kilograms, orders of magnitude less massive than standard neutrino detectors. The technique opens new ways to stress-test the known laws of physics and to detect the copious neutrinos produced in the hearts of collapsing stars. 'They finally did it,' says Kate Scholberg, a physicist at Duke University in Durham, North Carolina. 'And they have very beautiful result.' The experiment, called CONUS+, is described on 30 July in Nature. Challenging quarry Neutrinos are elementary particles that have no electrical charge and generally don't interact with other matter, making them extraordinarily difficult to detect. Most neutrino experiments catch these elusive particles by observing flashes of light that are generated when a neutrino collides with an electron, proton or neutron. These collisions occur extremely infrequently, so such detectors typically have masses of tonnes or thousands of tonnes to provide enough target material to gather neutrinos in relevant numbers. [Sign up for Today in Science, a free daily newsletter] Scholberg and her collaborators first demonstrated the mini-detector technique in 2017, using it to catch neutrinos produced by an accelerator at Oak Ridge National Laboratory in Tennessee. The Oak Ridge particles have slightly higher energies than those made in reactors. As a result, detecting reactor neutrinos was even more challenging, she says. But lower-energy neutrinos also allow for a more precise test of the standard model of physics. Scholberg's COHERENT detector was the first to exploit a phenomenon called coherent scattering, in which a neutrino 'scatters' off an entire atomic nucleus rather than the atom's constituent particles. Coherent scattering uses the fact that particles of matter can act as waves — and the lower the particles' energy, the longer their wavelength, says Christian Buck, a leader of the CONUS collaboration. If the wavelength of a neutrino is similar to the nucleus's diameter, 'then the neutrino sees the nucleus as one thing. It doesn't see the internal structure', says Buck, who is a physicist at the Max Planck Institute for Nuclear Physics in Heidelberg, Germany. The neutrino doesn't interact with any subatomic particles, but does cause the nucleus to recoil — depositing a tiny amount of energy into the detector. Catching sight of a nucleus Coherent scattering occurs more than 100 times as frequently as the interactions used in other detectors, where the neutrino 'sees' a nucleus as a collection of smaller particles with empty space in between. This higher efficiency means that detectors can be smaller and still spot a similar number of particles in the same time frame. 'Now you can afford to build detectors on the kilogram scale,' Buck says. The downside is that the neutrinos deposit much less energy at the nucleus. The recoil induced on a nucleus by a neutrino is comparable to that produced on a ship by a ping-pong ball, Buck says — and has until recent years has been extremely challenging to measure. The CONUS detector is made of four modules of pure germanium, each weighing 1 kilogram. It operated at a nuclear reactor in Germany from 2018 until that reactor was shut down in 2022. The team then moved the detector, upgraded to CONUS+, to the Leibstadt nuclear power plant in Switzerland. From the new location, the team now reports having seen around 395 collision events in 119 days of operation — consistent with the predictions of the standard model of particle physics. After COHERENT's landmark 2017 result, which was obtained with detectors made of caesium iodide, Scholberg's team repeated the feat with detectors made of argon and of germanium. Separately, last year, two experiments originally designed to hunt for dark matter reported seeing hints of low-energy coherent scattering of neutrinos produced by the Sun. Scholberg says that the standard model makes very clean predictions of the rate of coherent scattering and how it changes with different types of atomic nucleus, making it crucial to compare results from as many detecting materials as possible. And if the technique's sensitivity improves further, coherent scattering could help to push forward the state of the art of solar science. Researchers say that coherent scattering will probably not completely replace any existing technologies for detecting neutrinos. But it can spot all three known types of neutrino (and their corresponding antiparticles) down to low energies, whereas some other techniques can capture only one type. This ability means it could complement massive detectors that aim to pick up neutrinos at higher energies, such as the Hyper-Kamiokande observatory now under construction in Japan. This article is reproduced with permission and was first published on July 30 2025. Solve the daily Crossword
Newsweek
a day ago
- Newsweek
A Doctor's Plea From a Nation Asleep on Brain Disease
Advocates for ideas and draws conclusions based on the interpretation of facts and data. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As a physician who once treated pain, I now endure the unimaginable. Amyotrophic lateral sclerosis (ALS) has left me quadriplegic, dependent on a tracheostomy to breathe and a feeding tube to eat. Diagnosed at 35, my career ended abruptly. My family's story reveals the scale of the coming storm—my father battles Alzheimer's, my uncle succumbed to Parkinson's, and my grandmother to Lewy body dementia. We are not outliers; we represent a silent epidemic. Neurodegenerative diseases are surging, yet our nation slumbers, unaware of the devastation ahead. The public's complacency is by design, built on a statistical illusion. ALS, fatal since 1869, exemplifies this peril. With a median survival of 2-3 years, it strikes about 1 in 300 people in their lifetime, which predicts that over 1 million people now alive in the U.S. will succumb to ALS. Yet, under federal law, it is labeled "rare" because that definition is based on prevalence—a static snapshot of how many people are living with a disease at one time. Because ALS kills its victims so quickly, the number of living patients stays below the 200,000-person "rare" threshold. Its very lethality ensures it is never treated like the mainstream public health crisis it is. This paradox obscures a terrifying forecast: a projected 69 percent global increase in ALS cases by 2040. This illusion of rarity perpetuates a deadly inaction that extends to all brain diseases. Alzheimer's already affects over 7 million Americans and is projected to strike nearly 13 million by 2050, costing our economy $384 billion in 2025—and projected to nearly $1 trillion annually by mid-century. Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Exterior view of the headquarters of the U.S. Food and Drug Administration (FDA). Getty Images The failure to confront this crisis stems from a Tale of Two Agencies within the Food and Drug Administration (FDA). In 2017, Congress established the Oncology Center of Excellence (OCE), a dynamic hub that has revolutionized cancer treatment, accounting for 85 percent of all accelerated approvals in the last decade. This success is the result of focused will and resources; National Institutes of Health (NIH) funding for cancer has topped $7.2 billion, compared to $2.8 billion for neuroscience. Neurology has no such center. Lacking an institutional home, it is fragmented, slow, and characterized by a risk aversion unthinkable in oncology. This disparity persists because of the tragic nature of these diseases. In the 1980s, ACT UP activists staged "die-ins" to force a reluctant government to fight AIDS. Patients with ALS, Huntington's, or Alzheimer's cannot mount a similar protest—we are physically silenced and immobilized, unable to "seize the FDA." This vulnerability places a unique moral obligation on our leaders to act proactively on behalf of the voiceless. The new FDA leadership now arrives with bold promises of change, posing a question that haunts everyone touched by an untreatable neurological disease: Will this time be different? Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. vows to "sweep away barriers" and to "figure out new ways ... of accelerating approvals for drugs and treatments that treat rare diseases." FDA Commissioner Marty Makary has several times asked why it takes 10 years for a drug to get to market and proposes a "conditional approval" pathway based on a "plausible mechanism." Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad promised to "take action at the first sign of promise for rare diseases." For the ALS community, these words are now a crisis of credibility. In a disease that has a median survival of 2-3 years, we are asking for regulatory flexibility for a treatment that began its Phase 1 trial in 2011 and was granted FDA Fast Track designation in 2014. As a petitioner on the July 3 citizens' petition for a stem cell therapy known as NurOwn, my community has presented the FDA with a clear test. Ultimately, we are seeking accelerated approval based on new, unprecedented survival data from an expanded access program—data that exceeds the extension of survival of many approved cancer therapies. But the initial request is simpler: invite the sponsor to resubmit its application for a full review. Ours is a request for due process to give a voice to the voiceless—the lowest possible bar for the Trump administration to demonstrate its promised flexibility. A clear, bipartisan solution has already failed once. The Neuroscience Center of Excellence Act, introduced in 2021 to replicate oncology's success for brain disease, stalled in committee. It is time for our leaders to find the political will that has been so catastrophically absent. Congress must immediately revive and pass the Neuroscience Center of Excellence Act. The FDA, in turn, must match its leaders' promises with action by granting our petition a review. The science is poised for breakthroughs, but it is being shackled by a broken system. For those of us on a deadline, this is not a policy debate. It is a death sentence. Awaken now, before this silent storm engulfs us all. The voiceless can't wait. Dr. Shahriar Minokadeh, a former anesthesiologist trained at Johns Hopkins and pain management at UC San Diego, types via an eye-gaze device. The views expressed in this article are the writer's own.
